Gastric Adenocarcinoma Cell Models for Research

Gastric adenocarcinoma is the fifth most common cancer worldwide and the third leading cause of cancer-related death, with over 1.1 million new cases and 769,000 deaths in 2020 (WHO GLOBOCAN). The 5-year survival rate for localized gastric cancer is about 70%, but for metastatic disease it drops to approximately 6% (NCI SEER). Risk factors include Helicobacter pylori infection, smoking, high salt intake, and genetic predisposition (e.g., CDH1 mutations). The disease is often diagnosed at advanced stages, underscoring the need for better models to study progression and therapeutic resistance.

Gastric adenocarcinoma exhibits substantial molecular heterogeneity, with distinct subtypes defined by EBV status, microsatellite instability (MSI), genomic stability, and chromosomal instability (TCGA). This diversity makes it an ideal system for studying genotype-phenotype relationships and for developing precision medicine approaches. Public datasets such as TCGA and COSMIC provide extensive genomic and transcriptomic data, enabling researchers to identify driver mutations and to design gene-edited cell models that recapitulate specific alterations. Open questions include the role of clonal evolution, tumor microenvironment interactions, and mechanisms of resistance to targeted therapies.

Gastric adenocarcinoma arises from the accumulation of genetic and epigenetic alterations that activate oncogenic pathways and inactivate tumor suppressors. Key pathways include:

• • Wnt/β-catenin signaling: Mutations in CTNNB1 or loss of APC lead to nuclear β-catenin accumulation and transcriptional activation of MYC and cyclin D1.
• • p53 pathway: TP53 mutations (found in ~50% of cases) disrupt cell cycle checkpoints and apoptosis.
• • RTK/RAS signaling: Amplifications or mutations in ERBB2 (HER2), EGFR, KRAS, and MET drive proliferation and survival.
• • PI3K/AKT/mTOR: PIK3CA mutations or PTEN loss activate this pathway, promoting growth and metabolism.
• • TGF-β signaling: Mutations in TGFBR2 or SMAD4 impair growth inhibition and promote invasion.

These pathways are not mutually exclusive and often cooperate in tumorigenesis.

Data from TCGA and COSMIC reveal recurrent alterations in gastric adenocarcinoma:

Beyond individual genes, gastric adenocarcinoma is characterized by dysregulation of entire signaling networks:

• • Wnt/β-catenin: Key nodes include CTNNB1, APC, AXIN2, and TCF/LEF transcription factors. Overactivation promotes stemness and proliferation.
• • MAPK/ERK: KRAS, BRAF, and MEK are central; mutations lead to constitutive signaling and resistance to apoptosis.
• • PI3K/AKT: PIK3CA, PTEN, AKT, and mTOR regulate cell growth and survival; activation is common in MSI-high tumors.
• • JAK/STAT: IL-6/JAK/STAT3 signaling is often upregulated, contributing to inflammation and immune evasion.
• • Hippo/YAP: YAP/TAZ activation promotes cell proliferation and epithelial-mesenchymal transition (EMT).

These networks provide multiple targets for therapeutic intervention and for gene-editing strategies to create isogenic models.

Common gastric adenocarcinoma cell lines and their key mutations:

Organoids derived from patient tumors preserve the genetic heterogeneity and 3D architecture, making them valuable for drug testing and personalized medicine. They can be genetically modified using CRISPR to study gene function in a more physiologically relevant context.

Animal models are essential for studying tumor progression and therapeutic response in vivo:

• • Patient-derived xenografts (PDX): Implantation of patient tumor tissue into immunodeficient mice; retains patient-specific mutations and histology.
• • Genetically engineered mouse models (GEMM): Conditional knock-in of oncogenes (e.g., KRAS G12D) or knockout of tumor suppressors (e.g., TP53) in gastric epithelium using Cre-lox systems.
• • Induced models: Chemical carcinogens (e.g., N-methyl-N-nitrosourea) or Helicobacter pylori infection to induce gastric tumors.

These models are useful for validating gene function and for preclinical drug testing, but they are time-consuming and costly. Gene-edited cell lines offer a faster, more controllable alternative for initial screening.

CRISPR-based gene editing enables the creation of isogenic cell lines that differ only in a specific genetic alteration, providing a clean system to study gene function. For example:

• • TP53 knockout in AGS or MKN45 cells to study loss of tumor suppressor function.
• • KRAS G12D knock-in in wild-type lines to model oncogenic activation.
• • CDH1 knockout to investigate E-cadherin loss and EMT.
• • ERBB2 amplification models to study HER2-targeted therapy resistance.

These models are commercially available from various sources, with sequence-verified clones and quality control. They accelerate research by eliminating the need for labor-intensive cloning and validation. Custom gene-editing services can also generate tailored models for specific research questions.

Gene-edited cells are powerful tools for functional genomics, allowing researchers to determine the phenotypic consequences of specific mutations. For example:

• • Knockout screens: Using CRISPR libraries to identify genes essential for cell survival or proliferation in gastric cancer cells.
• • Knock-in studies: Introducing patient-specific mutations to assess their impact on drug sensitivity or invasion.
• • Reporter lines: Creating GFP-tagged proteins to track localization and dynamics.

These approaches help prioritize therapeutic targets and understand gene function in a controlled genetic background.

Isogenic cell line pairs (e.g., TP53 wild-type vs. knockout) are ideal for drug screening because they allow direct comparison of drug response without confounding genetic variability. Applications include:

• • High-throughput screening: Testing compound libraries on isogenic pairs to identify selective inhibitors.
• • Resistance modeling: Exposing cells to increasing drug concentrations to select for resistant clones, then identifying the genetic basis of resistance.
• • Combination therapy: Evaluating synergistic effects of drugs in the presence or absence of specific mutations.

Gene-edited models enable more accurate prediction of clinical response and help design rational combination strategies.

CRISPR-based synthetic lethality screens can identify genes that are essential only in the presence of a specific mutation, revealing potential biomarkers and therapeutic targets. For example:

• • In TP53-mutant gastric cancer cells, knocking out genes involved in DNA repair (e.g., PARP1) may cause cell death, suggesting PARP inhibitors as a targeted therapy.
• • In KRAS-mutant cells, synthetic lethal partners such as TBK1 or STK33 may be identified.

Gene-edited models also enable the discovery of secreted proteins or cell surface markers that can serve as diagnostic or prognostic biomarkers.

Researchers can access extensive genomic and functional data for gastric adenocarcinoma through the following databases: